30 January 2024
30 January 2024
UK monarch King Charles was discharged from hospital today following treatment for benign prostatic hyperplasia.
GAMMAGARD LIQUID is an intravenous immunoglobulin therapy for improving neuromuscular disability and impairment in affected individuals.
The approval of Rezzayo is based on the results of a Phase III randomised, double-blind and controlled clinical trial.
Results from a Phase III trial indicated that adding MSD’s blockbuster drug boosted survival rates in advanced bladder cancer patients.
The significance of Dr Barr’s statements reflects the relative strength of Merck (MSD)’s entry in the tumour necrosis factor (TNF)-like cytokine 1A (TL1A) drug class versus its competitors.
A decision from the European regulatory authority is anticipated in the second half of 2024.
An eye-catching milestone in hand, Ascidian will begin the Phase I/II STELLAR study of ACDN-01 for Stargardt disease in H1 2024.
The companies reprioritised their joint domvanalimab development programme to concentrate on the Phase III studies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
